Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer

2.1 Trastuzumab emtansine (Kadcyla, Roche), as a single agent, is indicated for 'the adjuvant treatment of adult patients with HER2‑positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2‑targeted therapy'.

2.2 The dosage schedule is available in the summary of product characteristics.

2.3 Trastuzumab emtansine costs £1,641.01 per 100‑mg vial and £2,625.62 per 160‑mg vial (powder for solution for infusion; excluding VAT; British national formulary online, accessed March 2020). The company has a commercial arrangement. This makes trastuzumab emtansine available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.